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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: In recent years, coxsackievirus B3 (CV-B3) has been determined as a
dominant enterovirus serotype that may cause severe complications in patients. Since 2008
in Taiwan, some enterovirus isolates have been regarded as untypeable [by employing com-
mercial immunofluorescence assay (IFA) kits]. In 2012, the number of isolates increased. Ge-
netic sequence analysis further confirmed that CV-B3 was present in most of the untypeable
viruses.
Methods: Isolates of CV-B3 were collected for basic local alignment search tool (BLAST) anal-
ysis and for phylogenetic analyses, based on VP1 gene sequences. In addition, the Taiwan Cen-
ters for Disease Control (Taiwan CDC) developed an in-house indirect IFA using polyclonal
antibodies (e.g., rabbit antisera) for diagnosis. The sensitivity and specificity were both eval-
uated by testing 61 reference enteroviruses and 307 local enteroviruses that were isolated be-
tween 1998 and 2010.
Results: Based on the results of the BLAST and phylogenetic analyses, five main genogroups
(i.e., GIeGV) were classified and the reference strains in Taiwan in previous years were primar-
ily clustered in the GV-A subgenogroup. However, the 15 CV-B3 isolates recently analyzed in
this study were classified in four different groups: GIII, GIV, GV-A, and GV-B. Among these
15 isolates, all 10 isolates in the GV-B group were initially reported as untypeable nonpolio en-
teroviruses when using commercial kits. The conditions of the in-house indirect IFA werend Diagnostic Center, Centers for Disease Control, Department of Health, Number 161, Kun-Yang
C.
(H.-S. Wu).
ed equally to this work.
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448 Y.-P. Huang et al.optimized by checkerboard titration, thereby resulting in a sensitivity of 100% and a specificity
of 98.5%.
Conclusion: This is the first report describing the phylogenetic relatedness of recent CV-B3
strains in Taiwan. An indirect IFA kit was developed by the Taiwan CDC for detecting CV-B3 vi-
ruses that are untypeable by commercial IFA kits.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Coxsackievirus B3 (CV-B3) is a member of the genus
Enterovirus of the family Picornaviridae. The genus
Enterovirus, which contains more than one hundred sero-
types, was originally composed of polioviruses, coxsack-
ievirus A, coxsackievirus B, and echoviruses on the basis of
differences in infectivity, cell tropism, antigenicity, and
pathogenicity.1,2 However, in recent years, the genus has
been reclassified (based on molecular characteristics) into
10 species: Human enterovirus A, Human enterovirus B,
Human enterovirus C, Human enterovirus D, Simian
enterovirus A, Bovine enterovirus, Porcine enterovirus B,
Human rhinovirus A, Human rhinovirus B, and Human
rhinovirus C. The CV-B3 and other 59 serotypes are now
members of Human enterovirus B.3 The picornavirus
genome is organized into four sections: (1) the 50 non-
translated region; (2) the single open reading frame
encoding a polyprotein; (3) the 30 nontranslated region; and
(4) the poly(A) tail. The polyprotein includes four structural
capsid proteins (i.e., VP4, VP2, VP3, and VP1) and seven
nonstructural proteins (i.e., 2A, 2B, 2C, 3A, 3B, 3C, and
3D). Virus isolation is traditionally used for the diagnosis of
enterovirus infection, whereas immunofluorescence assay
(IFA) and the neutralization test are used for serotyping and
antigenic characterization. Molecular diagnostic methods
now offer a faster and more sensitive alternative to tradi-
tional immunoassays and culture techniques and the
methods provide valuable information for genetic studies.1
However, because molecular diagnosis requires expensive
equipment and trained laboratory technicians, it is not yet
widely used in most clinical laboratories. In Taiwan, the IFA
is the method of choice to screen clinical specimens for
enteroviruses in the front end of the surveillance system.
According to our sentinel physician surveillance system,
more than 10,000 specimens are collected every year, and
more than 2000 enterovirus strains on average have been
isolated.4,5
The VP1 protein contains several major neutralization
antigenic sites and corresponds to its serotype, especially
in the prominent exterior loops (e.g., the BC loop and the
DE loop). Sequencing of the VP1 region has been used for
genotyping and phylogenetic analysis, and five genogroups
have been classified in CV-B31,2,6e8; however, only few
phylogenetic studies on CV-B3 are available.
Enteroviruses, particularly coxsackievirus B, are the
most common agents of viral myocarditis and are associ-
ated with dilated cardiomyopathy.9,10 In the years 1999,
2000, and 2005 in Taiwan, the CV-B3 was a very prevalent
enterovirus and was associated with severe complicationsin some patients.5,11 In 2008, some CV-B3 isolates were
furthermore initially untypeable by commercial IFA kits,
but they were finally confirmed by sequence analysis.
Therefore, the purpose of this study is to determine if
recent CV-B3 isolates are genetically and antigenically
distinct from isolates of earlier outbreaks. The Taiwan
Centers for Disease Control (Taiwan CDC) developed an in-
house IFA kit to evaluate the untypeable CV-B3 viruses used
in this study.
Materials and methods
Virus isolation and identification
Enteroviruses used in the study were collected and isolated
from patients with symptoms related to enterovirus infec-
tion (Table 1).5 For virus isolation, the Taiwan CDC
Collaborating Laboratories of Virology (TCCLV) used several
cell lines such as African green monkey kidney (Vero) cells,
human diploid fibroblast (MRC-5) cells, human lung carci-
noma (A549) cells, human epidermoid carcinoma (HEp-2)
cells, monkey kidney (LLC-MK2) cells, and rhabdomyosar-
coma (RD) cells. The isolates were identified by IFA using
commercial monoclonal antibodies (Light Diagnostics, Mil-
lipore Corporation, Billerica, MA, USA) and by the in-house
kit provided by the Taiwan CDC. These isolates, which
included nontypeable strains, were sent on a regular
monthly basis to the Taiwan CDC for further genotyping.
Viral RNA extraction, reverse transcription-
polymerase chain reaction, and sequencing
Viral RNA was extracted from 140 mL of culture supernatant
in accordance with the manufacturer’s instructions by using
the QIAamp Viral RNA Mini Kit (Qiagen, Santa Clara, CA,
USA). Extracted RNA was used in a one-step reverse
transcription-polymerase chain reaction (RT-PCR) of the
VP1 gene, as described previously.12,13 The products were
sequenced in both directions by using the BigDye Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA, USA) and an automated sequencer (ABI 3730;
Applied Biosystems, Foster City, CA, USA).
Phylogenetic analysis and selection analysis
By using BLAST software (National Center for Biotechnology
Information, Bethesda, MD, USA), genotyping was per-
formed by comparing the obtained sequences with se-
quences in the GenBank. The genotyping was then
Table 1 Yearly distribution of nonpolio enterovirus
isolatesa
Year No. of
NPEV
isolates
No. of
untypeable
NPEV
isolatesb
No. of CV-B3 isolatesc
Reported as
untypeable
NPEV
Reported
as NPEV
2007 2456 472 0 1
2008 4027 368 6 2
2009 2423 296 0 0
2010 3419 155 2 0
2011 3425 247 3 0
2012 2367 192 35d 83
Total 18,117 1730 46 86
a The EV isolates analyzed in this study were collected by the
surveillance systems under the Taiwan Centers for Disease
Control. The number was counted on the basis of the amount of
received isolates. The isolates were excluded from this study if
the patient information was incomplete.
b The isolates could not be identified by the immunofluores-
cence assay (IFA) kit.
c The information is based on genotyping results.
d Prior to the use of the in-house IFA kit, developed in May
2012, most CV-B3 isolates in 2012 were untypeable by IFA.
NPEV Z nonpolio enterovirus.
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by using the Molecular Evolutionary Genetics Analysis 5.03
(MEGA 5.03) software.14,15 The sequences determined in
the study were compared with reference sequences ob-
tained from GenBank and from previous surveillance re-
sults. The phylogenetic tree combined with a proteotyping
map using complete VP1 gene sequences was furthermore
performed to compare sequence differences. Phylogenetic
trees were constructed by using the neighbor-joining
method with 1000 replicates of bootstrap resampling.
Amino acid substitutions were visualized through a pro-
teotyping map. Different amino acids were indicated byTable 2 Prototype strains and clinical isolates of HEV and oth
specificity by using rabbit antiserum against coxsackievirus B3
Prototype strains (n Z 61)a
HEV-A CV-A2 to CV-A8, CV-A10, CV-A12,
CV-A14, CV-A16, enterovirus A71 (EV-A71)
HEV-B CV-A9, CV-B1, CV-B2, CV-B4 to
CV-B6, echovirus 1 (E-1) to E-7, E-9,
E-11 to E-21, E-24 to E-27, E-29 to
E-33, EV-B69, EV-B73, CV-B3
HEV-C CV-A11, CV-A13, CV-A17, CV-A18,
CV-A21, poliovirus 1 to poliovirus 3
(vaccine strain)
HEV-D EV-D68, EV-D70
Others Parechovirus 1, parechovirus 2
a Unless specifically indicated, only one strain is used.
E Z echovirus; EV Z enterovirus; HEV Z human enterovirus.single letter abbreviations in different colors. The amino
acid residues of each virus were presented on the x axis on
the map, and each virus was ordered according to the
phylogenetic tree on the y axis. Each column represented
the amino acid position, indicated by a selection criterion
of 5%. The sequences were edited by using BioEdit software
(Ibis Biosciences, Carlsbad, CA, USA).16 Nonsynonymous
(dN) and synonymous (dS) nucleotide substitutions were
used to examine the positive selection on the Datamonkey
webserver.17,18 A positive selection was defined as a dN
value greater than the dS value with p < 1.0. Three
methods were used to detect the site selection: (1) single-
likelihood ancestor counting (SLAC); (2) fixed effects like-
lihood (FEL); and (3) internal FEL (IFEL).18,19
Production of polyclonal antibodies
The CV-B3 strain E2005351, which was isolated in Taiwan,
was used as the immunogen for the antiserum preparation.
The strain was propagated in the RD cells and the 107.3/
50 mL 50% cell culture infectious dose (CCID50), calculated
by the Reed and Muench method,20 was determined before
administering the rabbit vaccinations. Anti-CV-B3 rabbit
serum was prepared, as described previously.21 In brief,
four New Zealand white rabbits were intravenously immu-
nized five times in a 2-day interval with 5 mL of UV-
inactivated virus stock. The rabbits received a final
booster of 10 mL of the virus stock on Day 42, and their sera
were tested for neutralization antibodies on Day 49. The
care and use of the rabbits were approved by the Institu-
tional Animal Care and Use Committee of The Taiwan CDC
to ensure compliance with the local legal and ethical
requirements.
Determination of neutralization antibody titers
After inactivation at 56C for 30 minutes, the rabbit anti-
sera were two-fold serially diluted in Dulbecco’s modified
Eagle medium (DMEM), and then examined forer pathogens used for the determination of sensitivity and
Clinical isolates (n Z 307)
CV-A2 (16 isolates), CV-A3 (25 isolates), CV-A4 (25 isolates),
CV-A5 (9 isolates), CV-A6 (9 isolates), CV-A8 (5 isolates),
CV-A10 (10 isolates), CV-A12 (5 isolates), CV-A16 (8 isolates),
EV-A71 (83 isolates)
E-3 (10 isolates), E-4 (2 isolates), E-6, E-7, E-11, E-16
(4 isolates), E-18 (6 isolates), E-25 (10 isolates), E-30
(8 isolates), E-33, CV-B1, CV-B2 (3 isolates), CV-B4
(3 isolates), CV-B5, CV-B3 (42 isolates)
CV-A21 (6 isolates)
EV-D68 (5 isolates)
Herpes simplex virus (5 isolates), influenza virus,
rhinovirus 31
Figure 1. Phylogenetic analysis of the coxsackievirus B3 strains, based on the complete VP1 gene sequence (852 nucleotides).
Phylogenetic analysis is based on the complete VP1 gene nucleotide sequences of reference strains from GenBank, from 38 Taiwan CV-
B3 isolates previously obtained by the surveillance system from 1999 through 2005, and from 15 representative Taiwan isolates from
2007 through 2012. The phylogenetic tree was constructed by using the Molecular Evolutionary Genetics Analysis (MEGA, version 5)
software, using the neighbor-joining method. The reliabilities were evaluated by using 1000 bootstrap replications. Only bootstrap
values of over 70% are shown. The 15 isolates from 2007 through 2012 are represented in italic boldface. Theblack dots indicate isolates
that were untypeable by the commercial IFA kit. The white triangles indicate the 38 isolates from 1999 through 2005. The reference
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50 mL of 100 CCID50 viruses of different CV-B3 sub-
genogroups and 50 mL of the aforementioned serially
diluted antiserum were incubated at 36C for 60 minutes.
A RD cell suspension (100 mL) containing approximately
5  104 cells was added afterward to each well. The
cytopathic effects (CPE) were observed daily during the
following 4 days. Neutralization titers are expressed as the
reciprocal of the highest serum dilution at which 50% of the
cells represent complete inhibition of the formation of CPE.
Indirect IFA and optimization of antiserum dilution
The procedure for IFA staining has been described previ-
ously.21 In brief, the rabbit antiserum is adequately pipet-
ted to cover each testing well on a glass slide. After
incubation for 30 minutes at 37C, the slide is washed with
phosphate-buffered saline (pH 7.2e7.4, 0.05% Tween 20)
and then dried. Ten microliters of fluorescein
isothiocyanate-conjugated goat anti-rabbit immunoglobulin
G (i.e., secondary antibody) is added to each well and
incubated for 30 minutes at 37C. After the slide is washed
and air dried, the fluorescence is observed. A positive result
was indicated by an apple-green color in the cytoplasm and
nucleus of infected cells. The optimization of antiserum
dilution was performed by using the serial dilution method.
Determination of sensitivity and specificity
The pretest was performed by using 61 prototype strains,
which consisted of human enterovirus A (HEV-A), HEV-B,
HEV-C, HEV-D, parechovirus 1, and parechovirus 2. Between
1998 and 2010, a total of 307 clinical isolates collected in
Taiwan were used for determining sensitivity and specificity
(Table 2). All tested isolates have been preidentified for
their serotypes or genotypes by RT-PCR and sequencing.
Statistical analysis
The neutralization antibody titers were compared between
the GV-A subgenogroup and other clusters by using the
Student t test with log10-transformed data. A p < 0.05
indicated statistical significance. The sensitivity and spec-
ificity and the 95% confidence interval values were calcu-
lated by using a web-based program (http://faculty.vassar.
edu/lowry/clin1.html). The kappa value and the 95% con-
fidence interval values between the indirect IFA method
and the molecular identification were calculated by using a
web-based program (http://faculty.vassar.edu/lowry/
kappa.html).
Nucleotide sequence accession numbers
The 53 nucleotide sequences of the VP1 gene determined in
this study have been deposited in the GenBank databasesequences are labeled in the order of year and abbreviated country
(i.e., CNZ China; FRZ France; DEZ Germany; MDZ Republic of M
substitutions were visualized through a proteotyping map. Differe
different colors. Each column represents the amino acid position, inunder the following IDs: JQ390174eJQ390219 and
JX027608eJX027614.
Results
Epidemiological results
The enterovirus isolates used in the study are listed in Table
1. After RT-PCR and sequencing, the VP1 gene sequences
obtained from these viruses were used for genotyping.
Based on the BLAST genotyping data, there was one CV-B3
isolate in 2007; eight CV-B3 isolates in 2008; zero CV-B3
isolates in 2009; two CV-B3 isolates in 2010; three CV-B3
isolates in 2011; and 118 CV-B3 isolates in 2012 (Table 1).
An obvious increase in CV-B3 infection was also detected in
early 2012. Six of the eight isolates in 2008, two isolates in
2010, three isolates in 2011, and most isolates in early 2012
were reported as untypeable nonpolio enteroviruses (NPEV)
by IFA using commercial monoclonal antibody (Light Di-
agnostics, Millipore Corporation, Billerica, MA, USA).
Phylogenetic analysis and selection analysis
For phylogenetic analysis, the following were used: the 15
Taiwan CV-B3 isolates in this study that were collected
from 2007 through 2012 (one strain was isolated in 2007
and in 2010; six strains in 2008; three strains in 2011, and
four strains in 2012) and 38 Taiwan CV-B3 isolates
randomly chosen from the reference isolates from 1999
through 2005. According to the phylogenetic tree (Fig. 1),
five main genogroups were classified (i.e., GIeGV), and
the strains isolated in Taiwan between 1999 and 2005 were
primarily clustered in the GV-A subgenogroup. The 15
isolates obtained between 2007 and 2012 were separated
into four different subgenogroups, as follows: one strain
each in GIII and in GIV; three strains in GV-A; and ten
strains in GV-B. In GV-B, all 10 isolates (i.e., E20081388,
E20081391, E20081392, E2010441, E2011439, E2011440,
E2012173, E2012172, E2012171, and E2011441) were
interestingly reported as untypeable NPEV. One unique
amino acid substitution at position 7 (valine to isoleucine)
was observed in 5 of 10 isolates in subgenogroup GV-B
when compared to the isolates in subgenogroup GV-A
(Fig. 1). No amino acid residue under positive selection
was identified.
Preparation of antienterovirus rabbit serum and
results of the neutralization test
Four anti-CV-B3 rabbit sera (#95, #96, #97, and #98) against
the GV-A subgenogroup (the predominant subgenogroup in
Taiwan) were used for the neutralization test. Table 3
shows the neutralization antibody titers against different
subgenogroups of CV-B3. There was an 8- to 64-fold
decrease in titers against the hetero-subgenogroup virusname of the coxsackievirus B3 strain-GenBank accession number
oldova; NLZ The Netherlands; USZ United States). Amino acid
nt amino acids are indicated by single-letter abbreviations in
dicated with a selection criterion of 5%.
Table 3 Neutralization antibody titers of rabbit antisera
against coxsackievirus B3 from different subgenogroups
Subgenogroup of the
CV-B3 virus (strain)
Antiserum no.
#95 #96 #97 #98
GV-A (E2005351)a 16,384 32,768 65,536 16,384
GIV* (E2000250) 1024 1024 1024 256
GV-B* (E20081391) 2048 512 1024 256
a The GV-A subgenogroup strain E2005351, which was isolated
in Taiwan, was used as the immunogen for the antiserum
preparation.
*Indicates a statistically significant difference in the log10-
transformed data, compared to the GV-A subgenogroup
(p < 0.05).
CV-B3 Z coxsackievirus B3.
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serum #95 was selected for the indirect IFA.
Indirect IFA and the determination of sensitivity
and specificity
The in-house antiserum #95 and three monoclonal anti-
bodies [i.e., mAbs catalog number 3360 of the pan-
enterovirus (pan-EV) blend, catalog number 3303 of a CV-
B blend, and catalog number 3306 of CV-B3] from the
commercial kit were used for the detection of different
genogroups among the CV-B3 isolates (Fig. 2). The isolate
E2005351 of the GV-A subgenogroup and the isolate
AFP2000250 of the GIV group were positive for all four an-
tibodies (panels AeD and panels EeH, respectively, in
Fig. 2). By contrast, the isolate E20081391 of the sub-
genogroup GV-B was negative for CV-B mAb (catalog
numbers 3303 and 3306), but positive for pan-EV mAb
(catalog number 3360) and antiserum #95 (panels IeL in
Fig. 2). The sensitivity of the indirect IFA was 100.0% (95%
confidence interval, 89.8e100.0%), as evaluated by using 43
CV-B3 viruses (i.e., one prototype strain and 42 clinical
isolates). The specificity was 98.5% (95% confidence inter-
val, 96.2e99.4%), calculated by using 325 non-CV-B3 iso-
lates (i.e., 60 prototype strains and 265 clinical isolates;
Table 2). The kappa value was 0.94 (95% confidence inter-
val, 0.88e0.99), indicating high reproducibility between
the indirect IFA method and molecular identification.
Discussion
Enterovirus infections are common in Taiwan. Hence, a
rapid and sensitive method is required for identifying the
serotype of an enterovirus. The neutralization test is the
gold standard for typing enteroviruses, but it is more
complicated and time consuming. The indirect IFA there-
fore has become a very common method that is used in
clinical diagnostics. Because commercial IFA kits now
identify only 19 enterovirus serotypes (i.e., poliovirus 1 to
poliovirus 3, CV-B1eCV-B6, CV-A9, CV-A16, CV-A24, E-4, E-
6, E-9, E-11, E-30, EV-D70, and EV-A71), the Taiwan CDC has
developed an indirect IFA kit for the serotyping of entero-
viruses CV-A2, CV-A4, CV-A5, CV-A6, and CV-A10, whichhave been circulating in Taiwan in recent years. The kit has
effectively reduced the quantity of untypeable enterovi-
ruses in clinical virology laboratories.21 In the past, the CV-
B3 virus could be identified by commercial IFA kits, except
for some isolates in Hong Kong.22 The IFA originally re-
ported several isolates as “untypeable”. However, since
2008 in Taiwan, the isolates have been finally confirmed as
CV-B3 by sequencing and neutralization tests.
CV-B3 was one of the most prevalent types of virus in
confirmed severe EV cases.5 Based on a previous study, five
genogroups are identified among the CV-B3 strains.8 This
study analyzed more than 100 VP1 nucleotide sequences in
CV-B3 strains isolated worldwide. Fifteen Taiwan isolates
were separated in four different subgenogroups (i.e., GV-A,
GV-B, GIII, and GIV). All 10 isolates in the GV-B sub-
genogroup interestingly were reported as “untypeable
NPEV” in the study, indicating that mutations in GV-B sub-
genogroup may contribute to the untypeable character-
istic. However, only one amino acid substitution at position
7 (i.e., valine to isoleucine) was observed on comparing
these isolates with other typeable Taiwan isolates in 2008.
The same amino acid substitution at the same position was
also present in the GIV strains, which first emerged in
Taiwan in 2000 and then disappeared quickly. However, the
difference of the IFA result was present between the old
GIV strains and the re-appeared isolate in 2008 (i.e.,
E20081389); the latter isolate was typeable by a commer-
cial IFA kit. Hence, more strains and studies are needed to
clarify the correlation between the amino acid substitution
and the untypeable characteristic. In addition, the amino
acid substitution at position 277 (i.e., threonine to alanine)
observed in some isolates in Hong Kong was possibly asso-
ciated with central nervous system disease.22 However, this
substitution was not displayed in these Taiwan isolates. By
contrast, there was one Taiwan isolate (i.e., E2012174) in
the GIII subgenogroup that contained older strains from the
1970s to 1980s and some strains in France from 2005 to
2006, but it is not easy to trace back the actual spread
route because of frequent international travel and trade
activities. An increase in CV-B3 infection furthermore
occurred in early 2012, and most isolates were reportedly
untypeable NPEV. This indicates that a useful diagnostic
tool is needed for the surveillance system, and that a po-
tential CV-B3 outbreak cannot be ignored.
The CV-B3 virus is a very common enterovirus serotype
circulating in Taiwan.11 In 2005, the clinical symptoms
caused by the CV-B3 virus were more complicated and
resulted in the deaths of several neonates in Taiwan. The
virus characteristics and herd immunity may have accoun-
ted for the CV-B3 recurrence in 1999e2000 and in 2005,
which included susceptible children and neonates. Viral
evolution may also influence circulation, and a new im-
ported subgenogroup or some new variants could cause a
new epidemic. For example, in 2008 the B5 subgenogroup
of EV-71 caused serious outbreaks in Taiwan.23 Because of
the potential for severe and fatal outbreaks, it is necessary
to monitor carefully the antigenic and genetic evolution of
the CV-B3 virus.
With the exception of the false-positive results with
herpes simplex virus (HSV), good sensitivity and specificity
were observed by the indirect IFA using rabbit antiserum in
this study. The same cross-reactivity with HSV was obtained
Figure 2. Photographs of IFA staining using an in-house IFA kit. The rhabdomyosarcoma (RD) cells infected with the coxsack-
ievirus B3 (CV-B3) isolates are stained and show positive apple-green fluorescence with the commercial IFA kit and the in-house IFA
kit (400 magnification). Three CV-B3 genogroups were used: isolate E2005351 in genogroup GV-A (panels A, B, C, and D); isolate
AFP2000250 in genogroup GIV (panels E, F, G, and H); and isolate E20081391 in genogroup GV-B (panels I, J, K, and L). The CV-B3
isolates were stained by monoclonal antibody catalog number 3360 of the Pan-Enterovirus Blend (panels A, E, and I); catalog
number 3303 of the CV-B blend (panels B, F, and J); catalog number 3306 of CV-B3 (panels C, G, and K); and antiserum #95 (panels
D, H, and L). However, the isolate E20081391 was untypeable by catalog numbers 3303 and 3306.
Phylogenetic analysis and development of IFA for CV-B3 453when using different sources of rabbit sera before and after
immunization (data not shown), which demonstrates that
unknown components in rabbit serum may induce a
nonspecific reaction with HSV in the IFA method. A previous
study also reported cross-reactivity between HSV and rabbit
antiserum in the IFA kit.21 The false-positive result caused
by HSV could nevertheless be distinguished by different
cytopathic effects or by HSV-specific IFA.
In summary, the phylogenetic relatedness of the CV-B3
strains (isolated in Taiwan from 2007 through 2012) was
described and may help in understanding the evolution and
diversity of the virus. Some strains were untypeable by
using the commercial IFA kit and were classified in the GV-B
sugbenogroup. An indirect IFA kit for the detection of CV-B3
was developed. This kit was evaluated at The Taiwan CDC
and test results showed very good sensitivity (100%) and
specificity (98.5%). Because of the rapid evolution of en-
teroviruses and the potential of re-emerging pathogens and
severe outbreaks, a regular surveillance system and
continually improved diagnostic methods are needed.Conflicts of interest
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